Bienvenido

Amplification of brain self-repair processes translating into persistent functional recovery.

A 3-month course with NeuroAiD:

• Increases by 50% the odds of achieving functional independence at 6 months.¹

• Enhances persistent functional recovery and independence on top of rehabilitation for up to 2 years.^1,2,3

• Improves motor recovery with benefits observed as early as 1 month of treatment and at each time point up to 3 months.⁴

The CHIMES-E Study, functional recovery over 2 years.¹

• Pre-planned study on 880 subjects* with Acute Ischaemic Stroke followed up for 2 years.

• Randomised to 3 months of either NeuroAiD or placebo.

+50% in odds of achieving functional independence at 6 months.

Persistent recovery with benefits observed over 2 years

In subjects with 2 to 4 prognostic factors of poorer outcome** and receiving NeuroAiD² :

• More subjects achieved functional independence over time versus placebo.

• Significant improvements observed as early as 3 months.

• Less subjects deteriorating over time versus placebo, illustrating the persistence of the recovery

*CHIMES-E published in Cerebrovascular Diseases journal is the pre-planned extended follow-up to 24 months of the CHIMES study⁵, a 3-month study conducted on 1099 subjects. The CHIMES study was published in Stroke journal in 2013. **Prognostic factors are defined as older age, female sex, baseline NIHSS score ≥ 10 and time to first dose 48h.

---

Combining NeuroAiD and Rehabilitation doubles the odds of achieving functional independence versus Rehabilitation alone.³  

• Analysis of 380 subjects having received rehabilitation during 3 months of NeuroAiD (n=200) or placebo (n=180).

+50% in odds of achieving functional independence at 6 months.

Persistent recovery with benefits observed over 2 years

• Statistically significant odds ratio at all time points from 3 months to 2 years from stroke onset.

• Persistent recovery with benefits sustained for up to 2 years, as supported by low Numbers Needed to Treat (NNT) range from 5 to 7 over the 24-month follow-up period.

---

NeuroAiD improves motor recovery.⁴

• Randomised double-blind study placebo-controlled study in post-acute stroke subjects with upper and lower limbs deficits, included up to one month following an ischaemic stroke (n=150).

Significantly better motor recovery observed since month 1 and sustained up to month 3.

 

 

By stimulating brain neurorepair processes, NeuroAiD enhances recovery after a TBI

• Improves 2 of the most commonly impacted cognitive domain post-TBI⁶

• Enhances functional outcome to reach independency in moderate and severe TBI⁷

---

The BRAINS study⁶

• Randomized, placebo-controlled pilot trial on 79 mild to moderate TBI subjects.

• Recruited from 1 month to 12 months from TBI.

• Receiving 6 months of NeuroAiD or matching placebo and followed-up until 9 months.

• Continuous improvement of Executive Functioning, significant at 6 months.

• Executive Functioning deficit is directly impacting activities of daily living and affecting cognitive rehabilitation.

• Continuous improvement of Complex Attention, significant at 6 months.

• Complex Attention is one of the most impacted cognitive domains following a TBI.

---

Recovering functional outcomes post-TBI⁷

• Randomised, double-blind, placebo-controlled trial in 81 subjects after a moderate to severe TBI.

• Treatment initiated within 24 hours from TBI onset from a 6-month course.

• Dosing schedule: NeuroAiD (MLC901) or placebo at a regimen of 2 capsules, 3 times per day for 6 months.

• Assessment: GOS and modified Rankin Scale (mRS) at month 3 and month 6.

NeuroAiD optimises recovery of moderate and severe TBI subjects over time

• Higher rate of subjects with favourable outcome in NeuroAiD group compared to placebo group at month 3.

• Over 86% of the subjects reached favourable outcome in NeuroAiD group after a 6-month course (including 43.2% with GOS 5).

• Significant differences in favour of NeuroAiD at both time points.